BridgeBio Pharma's Data From ATTRibute-CM Open-Label Extension Study Shows 44.7% Reduction In All-Cause Mortality, 49.3% In Cardiovascular Mortality Versus Placebo-To-Acoramidis; Acoramidis Well-Tolerated With No Long-Term Safety Concerns

BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a biopharmaceutical company focused on developing medicines for genetic conditions, today presented long-term efficacy and safety data from the ATTRibute-CM open-label extension (OLE) trial, demonstrating sustained clinical benefit of acoramidis through Month 54 in patients with ATTR-CM. These data were presented at the American College of Cardiology (ACC) Annual Scientific Sessions & Expo in a late-breaking oral presentation by Prem Soman, M.D., Ph.D. of University of Pittsburgh School of Medicine and it was the only ATTR-CM presentation selected for the ACC late-breaker session. These data are now simultaneously published in JAMA Cardiology. Acoramidis is the only selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer.